Entremed (ENMD)

[tborges]

There were only 10 patients enrolled in the trial and any results would have to be validated in a larger patient population.

It appears that the next step was to find a biomarker to determine those patients most likely to respond to Panzem. "...Dr. Sidor further commented, “Breast cancer remains a significant health problem, killing over 40,000 American women annually, despite the introduction of new therapies. A primary resistance mechanism to chemotherapeutic agents is thought to be the upregulation of HIF-1a and Panzem® is a potent inhibitor of HIF-1a. We hope that this study will also begin to identify biomarkers that we can use to further identify patients who would most benefit from treatment with Panzem® NCD...”

My guess is that this was back-burnered after the decision was made to focus on 2076 in December 2008.

In that press release Panzem was mentioned as a potential treatment for RA not TNBC...

"...While the Company’s other product candidates, including MKC-1, ENMD-1198 and Panzem® in rheumatoid arthritis, continue to be promising, the Company will consider further clinical development only if additional financial resources are available. As a result, the Company expects to reduce all research activities to the minimal level necessary to continue its efforts to realize their potential value through arrangements with third parties. The Company’s plan for these programs is not expected to affect ongoing trials and current patients..."

...and we all know that there were no "third parties" stepping forward...